Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery

Duminda N. Wijeysundera, Muhammad Mamdani, Andreas Laupacis, Lee A. Fleisher, W. Scott Beattie, Sindhu R. Johnson, Jonathan Kolstad, Mark D. Neuman

Research output: Contribution to journalArticle

Abstract

Background-Largely on the basis of 2 randomized trials published in the 1990s, β-blockers were initially promoted as an evidence-based intervention for preventing cardiac complications of noncardiac surgery. However, subsequent studies raised concerns about a widespread use of perioperative β-blockade. Little is known regarding how this changing evidence influenced the use of perioperative β-blockers in clinical practice. Methods and Results-We conducted a population-based, time-series analysis (April 1999 to March 2010) among residents of Ontario, Canada (age 66 years and older), to evaluate the influence of research publications and practice guidelines on rates of new β-blocker prescriptions before major elective noncardiac surgery. In an analysis of 249 828 procedures, the rate of new β-blocker prescriptions increased from 26.3 per 1000 procedures in April 1999 to 62.7 per 1000 procedures in the first quarter of 2005, after which it decreased to 19.7 per 1000 procedures by March 2010. We observed a marked decrease in prescriptions (P=0.004) during early 2005, without any preceding publications that raised concerns about perioperative β-blockade. There was no change (P=0.98) in prescription rates after the May 2008 publication of a multicenter, randomized trial that showed increased mortality from perioperative β-blockade. Prescribing trends remain unchanged after revisions of related practice guidelines in 2002 (P=0.28) and 2006 (P=0.53). Conclusions-After a period characterized by increasing adoption of preoperative β-blockade between 1999 and 2005, prescriptions rates subsequently fell from 2005 to 2010. Further research is needed to understand the basis for these changes, which are only partially explained by evidence of potential harm.

Original languageEnglish (US)
Pages (from-to)558-565
Number of pages8
JournalCirculation: Cardiovascular Quality and Outcomes
Volume5
Issue number4
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Practice Guidelines
Prescriptions
Publications
Ontario
Research
Multicenter Studies
Canada
Mortality
Population

Keywords

  • β-blockers
  • Coronary artery disease
  • Health services research
  • Surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wijeysundera, D. N., Mamdani, M., Laupacis, A., Fleisher, L. A., Beattie, W. S., Johnson, S. R., ... Neuman, M. D. (2012). Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery. Circulation: Cardiovascular Quality and Outcomes, 5(4), 558-565. https://doi.org/10.1161/CIRCOUTCOMES.112.965632

Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery. / Wijeysundera, Duminda N.; Mamdani, Muhammad; Laupacis, Andreas; Fleisher, Lee A.; Beattie, W. Scott; Johnson, Sindhu R.; Kolstad, Jonathan; Neuman, Mark D.

In: Circulation: Cardiovascular Quality and Outcomes, Vol. 5, No. 4, 07.2012, p. 558-565.

Research output: Contribution to journalArticle

Wijeysundera, DN, Mamdani, M, Laupacis, A, Fleisher, LA, Beattie, WS, Johnson, SR, Kolstad, J & Neuman, MD 2012, 'Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery', Circulation: Cardiovascular Quality and Outcomes, vol. 5, no. 4, pp. 558-565. https://doi.org/10.1161/CIRCOUTCOMES.112.965632
Wijeysundera, Duminda N. ; Mamdani, Muhammad ; Laupacis, Andreas ; Fleisher, Lee A. ; Beattie, W. Scott ; Johnson, Sindhu R. ; Kolstad, Jonathan ; Neuman, Mark D. / Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery. In: Circulation: Cardiovascular Quality and Outcomes. 2012 ; Vol. 5, No. 4. pp. 558-565.
@article{37d248ddd85d4abfb9b54ff59ede5ab1,
title = "Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery",
abstract = "Background-Largely on the basis of 2 randomized trials published in the 1990s, β-blockers were initially promoted as an evidence-based intervention for preventing cardiac complications of noncardiac surgery. However, subsequent studies raised concerns about a widespread use of perioperative β-blockade. Little is known regarding how this changing evidence influenced the use of perioperative β-blockers in clinical practice. Methods and Results-We conducted a population-based, time-series analysis (April 1999 to March 2010) among residents of Ontario, Canada (age 66 years and older), to evaluate the influence of research publications and practice guidelines on rates of new β-blocker prescriptions before major elective noncardiac surgery. In an analysis of 249 828 procedures, the rate of new β-blocker prescriptions increased from 26.3 per 1000 procedures in April 1999 to 62.7 per 1000 procedures in the first quarter of 2005, after which it decreased to 19.7 per 1000 procedures by March 2010. We observed a marked decrease in prescriptions (P=0.004) during early 2005, without any preceding publications that raised concerns about perioperative β-blockade. There was no change (P=0.98) in prescription rates after the May 2008 publication of a multicenter, randomized trial that showed increased mortality from perioperative β-blockade. Prescribing trends remain unchanged after revisions of related practice guidelines in 2002 (P=0.28) and 2006 (P=0.53). Conclusions-After a period characterized by increasing adoption of preoperative β-blockade between 1999 and 2005, prescriptions rates subsequently fell from 2005 to 2010. Further research is needed to understand the basis for these changes, which are only partially explained by evidence of potential harm.",
keywords = "β-blockers, Coronary artery disease, Health services research, Surgery",
author = "Wijeysundera, {Duminda N.} and Muhammad Mamdani and Andreas Laupacis and Fleisher, {Lee A.} and Beattie, {W. Scott} and Johnson, {Sindhu R.} and Jonathan Kolstad and Neuman, {Mark D.}",
year = "2012",
month = "7",
doi = "10.1161/CIRCOUTCOMES.112.965632",
language = "English (US)",
volume = "5",
pages = "558--565",
journal = "Circulation: Cardiovascular Quality and Outcomes",
issn = "1941-7713",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Clinical evidence, practice guidelines, and β-blocker utilization before major noncardiac surgery

AU - Wijeysundera, Duminda N.

AU - Mamdani, Muhammad

AU - Laupacis, Andreas

AU - Fleisher, Lee A.

AU - Beattie, W. Scott

AU - Johnson, Sindhu R.

AU - Kolstad, Jonathan

AU - Neuman, Mark D.

PY - 2012/7

Y1 - 2012/7

N2 - Background-Largely on the basis of 2 randomized trials published in the 1990s, β-blockers were initially promoted as an evidence-based intervention for preventing cardiac complications of noncardiac surgery. However, subsequent studies raised concerns about a widespread use of perioperative β-blockade. Little is known regarding how this changing evidence influenced the use of perioperative β-blockers in clinical practice. Methods and Results-We conducted a population-based, time-series analysis (April 1999 to March 2010) among residents of Ontario, Canada (age 66 years and older), to evaluate the influence of research publications and practice guidelines on rates of new β-blocker prescriptions before major elective noncardiac surgery. In an analysis of 249 828 procedures, the rate of new β-blocker prescriptions increased from 26.3 per 1000 procedures in April 1999 to 62.7 per 1000 procedures in the first quarter of 2005, after which it decreased to 19.7 per 1000 procedures by March 2010. We observed a marked decrease in prescriptions (P=0.004) during early 2005, without any preceding publications that raised concerns about perioperative β-blockade. There was no change (P=0.98) in prescription rates after the May 2008 publication of a multicenter, randomized trial that showed increased mortality from perioperative β-blockade. Prescribing trends remain unchanged after revisions of related practice guidelines in 2002 (P=0.28) and 2006 (P=0.53). Conclusions-After a period characterized by increasing adoption of preoperative β-blockade between 1999 and 2005, prescriptions rates subsequently fell from 2005 to 2010. Further research is needed to understand the basis for these changes, which are only partially explained by evidence of potential harm.

AB - Background-Largely on the basis of 2 randomized trials published in the 1990s, β-blockers were initially promoted as an evidence-based intervention for preventing cardiac complications of noncardiac surgery. However, subsequent studies raised concerns about a widespread use of perioperative β-blockade. Little is known regarding how this changing evidence influenced the use of perioperative β-blockers in clinical practice. Methods and Results-We conducted a population-based, time-series analysis (April 1999 to March 2010) among residents of Ontario, Canada (age 66 years and older), to evaluate the influence of research publications and practice guidelines on rates of new β-blocker prescriptions before major elective noncardiac surgery. In an analysis of 249 828 procedures, the rate of new β-blocker prescriptions increased from 26.3 per 1000 procedures in April 1999 to 62.7 per 1000 procedures in the first quarter of 2005, after which it decreased to 19.7 per 1000 procedures by March 2010. We observed a marked decrease in prescriptions (P=0.004) during early 2005, without any preceding publications that raised concerns about perioperative β-blockade. There was no change (P=0.98) in prescription rates after the May 2008 publication of a multicenter, randomized trial that showed increased mortality from perioperative β-blockade. Prescribing trends remain unchanged after revisions of related practice guidelines in 2002 (P=0.28) and 2006 (P=0.53). Conclusions-After a period characterized by increasing adoption of preoperative β-blockade between 1999 and 2005, prescriptions rates subsequently fell from 2005 to 2010. Further research is needed to understand the basis for these changes, which are only partially explained by evidence of potential harm.

KW - β-blockers

KW - Coronary artery disease

KW - Health services research

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84864581713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864581713&partnerID=8YFLogxK

U2 - 10.1161/CIRCOUTCOMES.112.965632

DO - 10.1161/CIRCOUTCOMES.112.965632

M3 - Article

VL - 5

SP - 558

EP - 565

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

SN - 1941-7713

IS - 4

ER -